3 not yet recruiting, 1 completed, 1 recruiting. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Not yet recruiting 3, Completed 1 |
Follow Bispecific Antibody: new trials by email Literature Review of Bispecific Antibody trials Research Report on Bispecific Antibody
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma Glofitamab; Polatuzumab vedotin; Zuberitamab; Cyclophosphamide; Doxorubicin; Prednisone - DLBCL - Diffuse Large B Cell Lymphoma, Chemo-free Therapy | Phase 2 | Not yet recruiting | Li Zhiming | 40 | 2026-01-15 | 2025-11-19 |
| Pragmatic Geriatric Assessment Before CAR-T or Bispecific Antibody Therapy to Predict Side Effects and Outcomes in Older Patients (GA-ACT Trial) pragmatic geriatric assessment - Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, CART Therapy | Recruiting | University of Zurich | 208 | 2025-12-12 | 2025-12-30 | |
| A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC Ivonescimab+Chemo, Penpulimab+Chemo - NSCLC, Neoadjuvant Therapy | Phase 2 | Not yet recruiting | Yang Fan, MD | 164 | 2025-07-31 | 2025-07-25 |
| Comparison of Neoadjuvant Cadonilimab Versus Chemotherapy Combined With PD-1 in the Treatment of Resectable Non-Small Cell Lung Cancer With High PD-L1 Expression: A Single-Center, Randomized, Exploratory Clinical Study AK104 - Resectable Non-small Cell Lung Cancer, Bispecific Antibody | Phase 2 | Not yet recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 80 | 2025-04-21 | 2025-04-27 |
| A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. Elranatamab - Elranatamab, Myeloma | Phase 2 | Completed | Pfizer | 39 | 2021-12-21 | 2026-09-29 |
Multiple Myeloma (2) · Blood Protein Disorders (1) · Cardiovascular Diseases (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Hematologic Diseases (1) · Hemorrhagic Disorders (1) · Hemostatic Disorders (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Lymphoma (1) · Lymphoproliferative Disorders (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms, Plasma Cell (1) · Paraproteinemias (1)
Hemic and Lymphatic Diseases (3) · Lymphatic Diseases (3) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Blood Protein Disorders (1) · Cardiovascular Diseases (1) · Hematologic Diseases (1) · Hemorrhagic Disorders (1) · Hemostatic Disorders (1) · Histiocytic Disorders, Malignant (1) · Histiocytosis (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Lymphoproliferative Disorders (1) · Neoplasms, Plasma Cell (1)
Cyclophosphamide (1) · Doxorubicin (1) · Drug Therapy (1) · Prednisone (1) · glofitamab (1) · polatuzumab vedotin (1)
Li Zhiming (1) · Pfizer (1) · Shanghai Pulmonary Hospital, Shanghai, China (1) · University of Zurich (1) · Yang Fan, MD (1)
China (3) · Switzerland (1)